Department of Intensive Care Unit, The First Affiliated Hospital of Guangxi Medical University, 6S Shuangyong Road, Nanning 530021, Guangxi, China; Department of Intensive Care Unit, The Affiliated Hospital of Guilin Medical University, 15S Lequn Road, Guilin 541001, Guangxi, China.
Department of Intensive Care Unit, The Affiliated Hospital of Guilin Medical University, 15S Lequn Road, Guilin 541001, Guangxi, China.
Am J Emerg Med. 2022 Apr;54:287-296. doi: 10.1016/j.ajem.2022.01.063. Epub 2022 Feb 3.
The use of vasopressors is vital in septic shock. However, the optimal timing of treatment remains unclear. Therefore, we aimed to explore the impact of early norepinephrine initiation on the survival of patients with septic shock.
We selected 4253 patients from the Medical Information Mart for Intensive Care IV database between 2008 and 2019. The primary outcome was 28-day mortality. Propensity score matching (PSM) was applied to minimize between-group imbalances, and a restricted mean survival time was used to quantify the beneficial impact of early norepinephrine treatment on survival. Sensitivity analyses were conducted to test the robustness of the study results in multiple cohorts.
In the PSM cohort, 2862 patients were equally assigned to early (receiving norepinephrine within the first 3 h) and delayed (> 3 h) norepinephrine initiation groups. Patients in the early norepinephrine initiation group received significantly less fluid therapy (0 vs. 79 mL/kg), had lower 28-day mortality (30.0% vs. 37.8%), longer survival days (21.89 vs. 20.37 days), shorter duration of intensive care unit (4.9 vs. 7.2 days) and hospital stays (12.4 vs. 13.6 days), shorter duration of supportive norepinephrine and invasive mechanical ventilation, lower incidence of organ failure progression (64.4% vs. 79.2%) within 24 h after shock onset, and higher mean arterial pressure within 6 and 24 h after shock onset than patients in the delayed norepinephrine initiation group (p < 0.05).
Norepinephrine initiation within the first 3 h, regardless of preload dependency, was associated with longer survival time and shorter duration of supportive norepinephrine and invasive mechanical ventilation and may delay or partially reverse rapid onset organ failure.
血管加压素在感染性休克中至关重要。然而,治疗的最佳时机仍不清楚。因此,我们旨在探讨早期去甲肾上腺素治疗对感染性休克患者生存的影响。
我们从 2008 年至 2019 年的医疗信息监护 IV 数据库中选择了 4253 名患者。主要结局为 28 天死亡率。应用倾向评分匹配(PSM)以尽量减少组间的不平衡,并使用受限平均生存时间来量化早期去甲肾上腺素治疗对生存的有益影响。进行敏感性分析以检验研究结果在多个队列中的稳健性。
在 PSM 队列中,2862 名患者被平均分配至早期(在最初 3 小时内接受去甲肾上腺素)和延迟(> 3 小时)去甲肾上腺素治疗组。早期去甲肾上腺素治疗组患者接受的液体治疗明显较少(0 毫升/千克 vs. 79 毫升/千克),28 天死亡率较低(30.0% vs. 37.8%),生存时间较长(21.89 天 vs. 20.37 天),重症监护病房(4.9 天 vs. 7.2 天)和住院时间(12.4 天 vs. 13.6 天)较短,支持性去甲肾上腺素和有创机械通气的持续时间较短(24 小时内器官衰竭进展发生率为 64.4% vs. 79.2%),休克发作后 6 小时和 24 小时的平均动脉压较高(p < 0.05)。
无论前负荷依赖性如何,在最初 3 小时内开始去甲肾上腺素治疗与更长的生存时间以及支持性去甲肾上腺素和有创机械通气的持续时间较短有关,并且可能延迟或部分逆转快速发作的器官衰竭。